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SUPPRESSION OF DGATI EXPRESSION IMPROVES HEPATIC STEATOSIS AND PREVENTS FAT INDUCED 
INSULIN RESISTANCE. 
Ameya Kulkarni, Cheal S. Choi" David Savage, Katsutaro Morino, Varman T. Samuel, Sheene Kim, Amy Wang, John 
G. Geis ler, Sanjay Bhanat, Brett Monia, Xing-Xian Yu, Susanne Neschen, Anthony 1. Romaneli, Gerald I. Shulman. 
Department of lntemol Medicine, Yale University School of Medicine, New Haven, cr. 
It is well known that metabolites resulting from Ihe accumulation of fat in tissue results in fatty liver, obesity, and 
insulin resistance. Because triglyceride synthesis is essential for this process, inhibition of the fi nal step afTO 
synthesis has been considered as a new therapeutic target for hepalosteatosis and insulin resistance. In this srudy, we 
investigated the metabolic impact of acyl eoA: diacylglycerol acyltransferase I (DGATI) and 2 (DGATI) supprc:::lsion. 
We used antisense oligonucleotides (ASOs) to reduce the expression of these enzymes in liver and fat in Sprague 
Dawley rats fed a 27% saffl ower oil high fat diet (HFD) for 4 weeks. Rats were injected with one of the fo llowing: 
saline, control ASO, DGATI ASO or DGATI ASO subcutaneously twice a week for 4 weeks. DOAT I and DGATI 
ASO treatment reduced DGATI and DOATI mRNA levels in liver by 95% and 57% respectively but only OGATI 
ASO lTeatment significarrtly reduced TO content when compared to the saline group. We detennined the effects of 
ASQ treatment on insulin nction in vivo during II 135 min hyperinsulinemic(4mU/kglmin)-euglycemic clamp. Glucose 
turnover and uptake were assessed using [3)H]glucosc infusion and {I-14C]2-deoxyglucose injection during clamps. 
DGA 1'2 ASO treated rats were protected from HFD induced insulin resistance as demonstrated by an 80"10 increase in 
glucose infusion rate (24.0±O.9 vs. I 3.4±1. I mg/kg/min, p<O.OO I). This wns accounted for by significant suppression 
of hepatic glucose production (82±6 vs. S3±11% p<O.OS) and a 54% increase in insulin-stimulated whole body glucose 
uptake (25.3± 1. 1 vs. 16.3±O.7 mglkglmin, p<O.OOI) when compared to the control ASO group. Insulin-stimulated 
glucose uptake in skeletal muscle and suppression of plasma free fatty acid levels during the clamp were also 
signifi cantly increased in DGAT2 ASO treated rats when compared to controls (200 uptake: 329BI vs. 263±28 
nmol/glmin, p=O.03, suppression ofFFA: 64±4 vs. 48±5%, p"'O.OI5). Of note, the DGATI ASO group showed less 
weight gain than controls despite the same food consumption over the treatment period . The ratio orweigl1t gain versus 
food consumption, efficiency of weight gain, was significantly lower in the DGAT2 group when compared to other 
groups, suggesting an increase in energy expenditure in the DGA 1'2 ASO group. 
In summary, this study demonstrates that the reduction orDGATI using an ASO prote<:ts against insulin resis tance in 
liver and peripheral tissue. 
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INTRODUCTION 
Type 2 Diabetes Mellitus has rapidly become an epidemic in the United States, with 
the number of people afflicted quickly approaching 17 million I , The problem is also 
growing worldwide, as it is estimated that 250 million people will be affected by the 
year 20205, Though the primary insult in the pathogenesis of type 2 diabetes is sti ll 
uncertain, insulin resistance has been implicated as a major contributor to the clinical 
manifestations of the disease. Several cross-sectional studies have shown insulin 
resistance in virtually all patients with type 2 diabetes. In addition, prospective 
studies have demonstrated the presence of insulin resistance up to two decades before 
the onset of the disease2,3,4. 
The intracellular events leading to insulin resistance are still relatively unknown. 
However, the search for the primary defect in this process has been greatly helped by 
an understanding of the nonnal insulin signaling cascade in both myocytes and 
hepatocytes. 
In skeletal muscle cells, insulin signaling begins with insulin binding to its receptor 
and inducing autophosporylation. This in tum activates tyrosine phosporylation of 
Insulin Receptor Substrate~ 1 (IRS-I), which activates phosphatidylinositol 3~kinase 
(pI-3 Kinase). PI-3 Kinase induces an intracellular signaling cascade involving AKT 
and other intennediates. The final result of this cascade is the translocation of the 
GLUT 4 receptor- the primary transporter of glucose into skeletal muscleS --onto the 
cellular membrane. In hepatocytes, IRS-2 phosporylation increases PI-3 kinase and 
AKT-2 activity. This in tum is thought to activate Glycogen Synthase Kinase 3 
Z 
(GSK3), resulting in an increase in glycogen synthesis-the primary insulin-mediated 
activity in the livers,zo, 
Further study of this cascade has implicated the elevation of intracellular lipids as a 
major contributor to the onset of insulin resistance in muscle and liver. A clear 
correlation between the accumulation of lipids in the liver and skeletal muscle and the 
development of insulin resistance has been repeatedly reported6,7,8,9. Several studies 
from Dr. Shulman's group and others have suggested that increasing intracellular 
fatty acid metabolites activate a serine/threonine kinase cascade (possibly initiated by 
PKC-9 in rodent muscle10) and subsequent activation of other serine kinases such as 
IKK-~ 11,1 2 and JNK_11 3 lead to phosporylation of serine sites on IRS-I, interfere with 
insulin stimulation ofPI3K and result in insulin resistanceS,14, A similar process has 
been suggested in liver, initiated by PKC-£ and mediated by tyrosine phosporylation 
ofIRS-Z", 
Triglycerides, as the major storage molecules for lipid in cells, are a primary source 
of intracellular fatty acid metabolites. Diacylglycerol acyl tr.ansferase (DGAT) 
catalyzes the final step in triglyceride synthesis by using diacylglycerol and acyl-
coenzyme A (acylCoA) (Figure 1), DGAT exists in two primary isofonns: DGA Tl 
and DGA TIIS. Although these isofonns are encoded by two separate gene families ls , 
both enzymes are ubiquitously expressed in tissues that are active in TO synthesis-
primarily the liver, adipose tissue, the intestinal epithelium, and epidennis. DGATI 
knockout mice have approximately 50% less TG in tissues l6 ,1 7 and are protected from 
obesity and diet induced insulin resistance through a mechanism involving increased 
energy expenditure, partially attributable to increased physical activityI6.17. Study of 
DGA T2 has been much more difficult, primarily because homozygous knockout of 
DGAT2 results in neonatal death due to severe lipopenia and impaired skin barrier 
function IS. 
3 
Comparative study of the two isofonns revealed vastly different enzymes. Genetic 
analysis showed little genetic homology between DGATI and 2, suggesting they 
came from different gene families l5, Other studies showed that suppression of one 
isofonn did not result in a compensatory increase in the atber l1, ls. Combined with the 
fact that the highest levels of expression ofDGATl are in small intestine and white 
adipose tissue, while DGAT2 is primarily expressed in liver and white adipose 
tissue]5, these data strongly suggest that the two enzymes play different roles in TG 
metabolism. Moreover, the extreme reduction in TO (approximately 90% in DGAT2 
KO carcass) suggests DOA T2 is more important in triglyceride synthesis than 
DGATI. However, no study to date has been able to examine the in vivo role of 
DGAT2 in triglyceride synthesis or the resulting effects on insulin resistance. 
To study the role that DGATI and DGA T2 play in triglyceride synthesis in vivo, we 
used antisense oligonucleotides (ASOs) to induce a deficiency in DOATI and 
DGAT2 expression in the setting of rats receiving fat enriched diets. Because ASOs 
are active in liver and adipose tissue but not in skeletal muscle l9, this study provides a 
unique model to study the effect of the isolated reduction of DGAT expression in 
liver and adipose tissue. Additionally, it allows an opportunity to study the effect of 
phannacologic reduction of triglyceride synthesis on fat induced insulin resistance. 
AIMS 
1) To characterize the effect of individual suppression ofDGATl and DGAT2 on 
hepatic steatosis under high fat feeding conditions. 
HYPOTHESIS : Suppression ofDGATl and DGAT2 will reduce hepatic steatosis in 
rats fed a high fat diet. 
2) To characterize the effect of individual suppression ofDGATl and DGAT2 on 
insulin mediated activity in liver and ske1etal muscle under high fat feeding 
conditions 
HYPOTHESIS: Both DGA T1 and DGAT2 suppression will protect high fat fed rats 




Note: All experimental protocols were completed by Ameya Kulkarni and Dr. Cheol 
SOD Choi unless otherwise stated. 
Animal Care and Treatments: Healthy male Sprague-Dawley (SD) rats weighing 
200-225 g were obtained from Charles River Laboratories (Wilmington, MA) and 
acclimated for four days after arrival and before initiation of the experiment. Rats 
were housed individually and maintained on a 12: 12 hour light dark cycle (lights on 
at 6:30 A1\1) with free access to food and water. Rats received either regular rodent 
chow (RC: 60 % carbohydrate (CHO)! l 0 % fatl30% protein) or a high fat diet 
(HFD: 26 % CHO/ 59 % fat/3D % protein). Safflower oil was the major constituent 
of the high fat diet (Dyets Inc., Bethlehem, PAl. We have previously shown that this 
diet produces hepatic steatosis and hepatic insulin resistance within 3 days20, Thus, 
intraperitoneal ASO therapy was initiated 3 days after commencing the high fat diet. 
All ASO, (control, DGATl and DGAT2) were prepared in norm.1 saline, and the 
solutions were sterilized through a 0.2 ~m filter. To suppress expression of the 
targeted gene, rats were dosed with ASO solutions or saline twice per week via 
intraperitoneal injection at a dose of 50· 75mgikg/week for 4 weeks. This study 
involved 6 treatment groups: Saline with regular chow (n=7), Saline with high fat diet 
(HFD) (n=7), DGAT1IHFD (n=11, ASO 50 m!¥Kglweek), DGAT2IHFD (n=9, ASO 
75mglKglweek) and two controIIHFD groups(scr.mbled ASO 50 or 75mg, n=9 and 5, 
respectively). During the treatment period, body weight and food intake were 
• 
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measured twice weekly. All procedures were approved by The Yale Animal Care and 
Use Committee. 
Selection of Rat DGAT ASOs: ASOs were selected and produced by Isis 
Phannaceuticals in Carlsbad, California. To identify rat DGAT I and 2 A80 
inhibitors, rapid throughput screens were perfonned in vitro21, In brief, eighty ASOs 
were designed to the rat DGATl and 2 mRNAs sequences and initial screens 
identified several potent and specific ASOs, all of which targeted a binding site 
within the coding region of the DGATI and 2 mRNAs. After extensive dose-response 
characterization of the most potent ASOs from the screen, two lead ASOs, ISIS-
327822 and 1818-369235 for DGA T1 and 2 respectively, were chosen. The control 
A80, 1818-141923, containing the sequence: 5'-CCTTCCCTGAAGGTTCCTCC-3', 
did not have perfect complementarity to any known gene in public databases. These 
ASOs contained a phosphoorthioate backbone, and in addition, the first and last five 
bases had a 2'-O-(2-methoxy)-ethyl(2'-MOE) modification. This chimeric design has 
been shown to provide both increased nuclease resistance and mRNA affinity, while 
maintaining the robust RNase H terminating mechanism utilized by these types of 
ASOS22 , These benefits result in an attractive in vivo pharmacological. and 
toxicological profile for 2' -MOE chimeric ASOs. 
Experimental Protocols: 
Two separate studies were performed after an overnight fast (food was removed at 
5:00 pm on the day before the experiment, and experiments were started at 
7 
approximately 9:00 am. 
Study 1: Hyperinsulinemic-E lIglycemic Clamp 
After the four week treatment period described above. hyperinsulinemic eugJycemic 
clamp studies were performed to measure peripheral and hepatic insulin sensitivities. 
Seven days prior to the clamp studies, Dr. Jianying Dong (rodent surgeon for Dr. 
Gerald Shulman) placed indwelling catheters into the right internal jugular vein 
extending to the right atrium, and the left carotid artery extending to the aortic arch. 
After the seven day waiting period and an overnight fast, [3-'H]-g1ucose (HPLC 
purified; Perkin Elmer, Boston, MA USA) was infused at a rate of 0.15 ).lei/min for 2 
hours to assess basal glucose turnover. Following the basal period, the 
hyperinsulinemic euglycemic clamp was conducted for 135 min with a 
primed/continuous infusion of human insulin (40 mU/kg prime, 4 mUlkglmin 
infusion) (Novo Nordisk, Princeton, NJ) and a variable infusion of20% dextrose to 
maintain euglycemia (-100 mg/dl). [3-' H]-g1ucose was infused at a rate of 0.4 
).lCi/min throughout the clamps to estimate insulin-stimulated whole body glucose 
fluxes, and 25 uCi of2-deoxy-D-[1-HC)glucose (DOG; Perkin Elmer. Boston, MA 
USA) was injected as bolus at the 75\11 minute ofthe clamp to estimate the rate of 
insulin-stimulated tissue glucose uptake23 . Blood samples for the measurement of 
plasma JH andlor 14C activities (60 Ill) w.ere taken at the end of basal period and 
every 10 min during the last 45 min of the clamp period. Additional blood samples 
(20 - 60f!1) were taken at 0, 70 and 135min for the determination of plasma free fatty 
acids and insulin concentrations. At the end of the clamp, rats were anesthetized with 
sodium pentobarbital injection (150mglkg) and all tissues were taken within 4 min. 
frozen immediately using liquid N2·coo!ed aluminum tongs, and stored at -BO°C for 
subsequent analysis. 
Study 2: Temporal Analysis 
8 
To study the metabolic effects of DGA T2 suppression over time, groups of rats 
receiving either high dose negative control ASO (75 mg'kglweek) or DGAT2 (75 
mg'kglweek) were treated for either 4 (n~8 and 8), 8 (n~8 and 8), 14 (n~8 and 8) or 
28 (n=6 and 7) days. In addition, rats receiving salinelRC (n=5), salinelHFD (n=5) Dr 
low dose negative control (50 mg'kglweek) (n~6) were treated for 28 days. Finally, 
one group was studied after a 3 day high fat diet with no ASO treatment (n~8). 
After the respective treatment periods and an overnight fast, fats were anesthetized 
using inhaled isoflorane. Soleus, gastrocnemius, tibalis anterior, quadriceps, and liver 
were collected using liquid Nrcooled aluminum tongs, and stored at -80°C for 
subsequent analysis. Liver and gastrocnemius were homogenized and triglycerides, 
diacylglycerols, and fatty acyl CoAs were measured as described below. mRNA was 
also isolated and quantified as described below. Plasma was collected from the portal 
vein as used for liver function tests and lipid profiles, as well as to measure insulin, 
leptin, adiponectin, and resistin. 
Biochemical Analysis and Calculations: Plasma glucose was analyzed during the 
clamps using 10 J..11 plasma by a glucose oxidase method on a Beckman glucose 
9 
analyzer 11 (Beckman, Fullerton, CA), Plasma insulin was measured by Aida 
Groszman at the Yale Radioimmunoassay Core Laboratories usmg 
radioimmunoassay kit from Linca Research (St. Charles, MO). Plasma Free Fatty 
Acid was detennined using an acyl-eoA oxidase based colorimetric kit (Wako Pure 
Chemical Industries, Osaka, Japan). For the detennination of plasma lH-glucose and 
J4C_2_DG, plasma was deproteinized with ZnS04 and Ba(OH)2. dried to remove 3H20, 
resuspended in water, and counted in scintillation fluid (Ultima Gold, Perkin Elmer, 
Boston MA) on a Beckman scintillation counter. Rates of basal and insulin-stimulated 
whole-body glucose turnover were detennined as the ratio of the [3.lH]-g]ucose 
infusion rate (disintegrations per minute [dpm] per minute) to the specific activity of 
plasma glucose (dpms per mg) at the end of basal period and during the final 30 min 
of the clamp experiment, respectively. Hepatic glucose output (HOO) was detennined 
by subtracting the glucose infusion rate from the total glucose appearance. The 
plasma concentration of 3H20 was determined by the difference between 3H counts 
without and with drying and whole body glycolysis was calculated from the rate of 
increase in plasma 3H20 concentration, detennined by linear regression of the 
measurements at 100, 105, 115, 125, and 135 min23. Whole body glycogen plus lipid 
synthesis was estimated by subtracting whole body glycolysis from whole body 
glucose uptake24• Glucose uptake and glycogen synthesis in individual muscles were 
calculated from muscle I·C-2-DG-6-P content and 3H incorporation to muscle 
glycogen, as previously described23. For the determination of muscle 14C_2_DG_6_ 
phosphate (2-DG-6-P) content, muscle samples were homogenized, and the 
supernatants were subjected to an ion-exchange column to separate 2-0G-6-P from 2-
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analyzer II (Beckman, Fullerton, CA). Plasma insulin was measured by Aida 
Groszman at the Yale Radioimmunoassay Core Laboratories using 
radioimmunoassay kit from Linco Research (St. Charles, MO). Plasma Free Fatty 
Acid was detennined using an acyl-eoA oxidase based colorimetric kit (Wako Pure 
Chemical Industries, Osaka, Japan). For the detennination of plasma 3H-glucose and 
14C_2_DG, plasma was deproteinized with ZnS04 and Ba(OHh, dried to remove 3H20, 
resuspended in water, and counted in scinti llation fluid (Ultima Gold, Perkin Elmer, 
Boston MA) on a Beckman scintillation counter. Rates of basal and insulin-stimulated 
whole-body glucose turnover were determined as the ratio of the [3.3H]-glucose 
infusion rate (disintegrations per minute [dpm) per minute) to the specific activity of 
plasma glucose (dpms per mg) at the end of basal period and during the final 30 min 
of the clamp experiment, respectively. Hepatic glucose output (HOO) was determined 
by subtracting the glucose infusion rate from the total glucose appearance. The 
plasma concentration of 3H20 was determined by the difference between 3H counts 
without and with drying and whole body glycolysis was calculated from the rate of 
increase in plasma 3H20 conce~tration, detennined by linear regression of the 
measurements at 100, 105, 115, 125, and 135 min23 . Whole body glycogen plus lipid 
synthesis was estimated by subtracting whole body glycolysis from whole body 
glucose uptake24 . Glucose uptake and glycogen synthesis in individual muscles were 
calculated from muscle 14C~2_DG_6~P content and 3H incorporation to muscle 
glycogen, as previously described23 . For the determination of muscle 14C~2~DG~6~ 
phosphate (2-DG-6-P) content, muscle samples were homogenized, and the 
supernatants were subjected to an ion-exchange column to separate 2~DG ~6-P from 2-
10 
DO as previously described2S , The radioactivity of 3H in muscle glycogen was 
determined by digesting muscle samples in KOH and precipitating glycogen with 
EtOH as previously described24. 
Insulin Signaling 
After a four week ASO treatment period (75 mglkglweek») these rats underwent a 1 00 
uU regular insulin bolus injection and tissues were harvested in-situ exactly 15 min 
after insulin stimulation. Liver samples harvested in-situ in fasting conditions (basal) 
were used to assess IR., and IRS·2 tyrosine phosphorylation. (0=11) IRS·} and IRS·2 
associated PI3 kinase activity (0=12), Akt2 activity (0=13). Soleus muscles were used 
for IR, and IRS-I tyrosine phosphorylation, (n=ll) IRS-I associated P13 kinase 
activity (n=12), Aktl activity (0=13). Primary antibodies used for these experiments 
were rabbit polyclonal IgO obtained from Upstate (Charlottesville, VA). For 
assessment of tyrosine phosphorylation, after the membrane was blotted with anti-
phosphotyrosine antibody, it was stripped and reb lotted with the same antibody used 
for immunoprecipitation to assess any differences in total protein (i.e. IR. IRS 1 or 
IRS2) present. Antibody and immunoprecipitation experiments were carried out by 
Dr. Xian Chung. 
Tissue Lipid Measurement: The following experiments were completed by Dr. Gary 
Cline. After purification, fatty acyl-eoA fractions were dissolved in methanol/H20 
(1: I, v/v) and subjected to LCIMSIMS analysis26,21, A turbo ionspray source was 
interfaced with an API 3000 tandem mass spectrometer (Applied Biosystems, Foster 
City, CA) in conjunction with two Perkin Elmer 200 Series micro pumps and a 200 
11 
Series autosampler (Perkin Elmer, Norwalk, CT). The transition pairs [M-2H]2-:[M-
H-80]- (QI and Q3) were monitored in negative MRM mode for each fattyacyl -CoA 
species. Total fatty acyl-eoA content is expressed as the sum of individual species. 
An aliquot of the organic phase was retained for measurement of diacylglycerol 
content. This was passed over preconditioned columns (Waters Sep-Pak Cartridge 
WAT020845. Milford, Massachusetts) to purify the DAG component. Using mass 
spectrometry the transition pairs [M+H-18]+: fatty acids from DAG (QI and Q3) 
were monitored in + MRM mode for each DAG metabolite. Total DAG content is 
expressed as the sum of individual species, Tissue triglyceride was extracted using 
the method ofBligb and Dyer26 and measured using a DeL Triglyceride Reagent 
(Diagnostic Chemicals Limited, P.E.!. Canada). 
Determination of Triglyceride Synthesis and Fatty Acid Oxidation in Transfeeted 
Rat Hepatoeytes In Vitro 
The following experiments were completed by collaborators at l sis Pharmaceuticals 
in Carlsbad California. 
Trigylceride synthesis in transfected rat hepatocytes was determined by measuring the 
incorporation of radio labeled glycerol into triglycerides l8. After a 24 hour recovery, 
transfected cells cultured into 60-tpIll plates were switched to 1 ml of high glucose 
DMEM medium containing 10% FBS, 0.5% BSA and 10 uCi of [,H]glycerol with or 
without addition of 0.5 mM oleate and cultured overnight. The cells were then 
harvested. One fraction of the harvested cell s were used for RNA extraction and gene 
expression analysis hexane/isopropanol (3:2 in volume) mixture. The extracted lipids 
12 
were separated by TLC. The amount of incorporated [3H]g1yceroJ into triglyceride 
was detennined by liquid scintillation counting. Fatty acid oxidation in the 
transfected hepatocytes were detennined by measuring the oxidation of [14C]oleate 
into acid soluble products and C02
28
. Briefly, hepatocytes cultured in 25-cm2 flasks 
were washed with PBS once and incubated with 2 mllow glucose DMEM plus 0.25% 
BSA and 0.25 uCi of [14C]oleic acid (Amersham Biosciences). The flasks were 
capped with a rubber stopper and gassed with O,-CO, (95%-5%). After 3 h 
incubation, 1 ml of medium was mixed with 100 ul of 1 0% BSA and then with 100 ul 
of 60% HCI04. After centrifugation, 1 mI of the supernatant was counted to 
determine the levels of soluble 14C-products. Radiolabeled CO2 was trapped in a well 
contained 50 ul of 35% NaOH and directly detennined by liquid scintillation counting. 
Total RNA Preparation and Real-time Quantitative RT-PCR Analysis 
The following experiments were completed by Ameya Kulkarni with significant 
assistance from Dr. David Savage and Amy Wang. 
Total RNA was extracted from harvested hepatocytes or tissues using total RNA 
isolation reagent (#BL-l 0500, Biotecx Laboratories Inc, Houston TX) according to 
manufacturer's instructions. Real-time quantitative RT -PCR was perfonned using 
custom-made RT-PCR enzymes and reagents kit (Invitrogen Life Technology Inc, 
Carlsbad, CAl and ABI Prism 7700 Sequence Detector (PE Applied Biosciences, 
Foster City. CA). Primers and probes for analysis of the expression of different genes 
were designed using Primer Express Software (PE Applied Biosciences, Foster City, 
CAl· 
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were separated by TLC. The amount of incorporated eH]glycero] into triglyceride 
was determined by liquid scintillation counting. Fatty acid oxidation in the 
transfected hepatocytes were determined by measuring the oxidation of e4C]oieate 
into acid soluble products and C02
ZS
, Briefly, hepatocytes cultured in 25-cm2 flasks 
were washed with PBS once and incubated with 2 ml10w glucose DMEM plus 0.25% 
BSA and 0.25 uCi of [14C]oleic acid (Amersham Biosciences). The flasks were 
capped with a rubber stopper and gassed with 02-C02 (95%-5%). After 3 h 
incubation, 1 ml of medium was mixed with 100 ul of 10% ESA and then with 100 ul 
of 60% HCI04 . After centrifugation, 1 ml of the supernatant was counted to 
detennine the levels of soluble 14C-products. Radiolabeled CO2 was trapped in a well 
contained 50 ul of35% NaOH and directly detennined by liquid scintillation counting. 
Total RNA Preparation and Real-time Quantitative RT-PCR Analysis 
The following experiments were completed by Ameya Kulkarni with significant 
assistance from Dr. David Savage and Amy Wang. 
Total RNA was extracted from harvested hepatocytes or tissues using total RNA 
isolation reagent (#BL-I 0500, Biotecx Laboratories Inc, Houston TX) according to 
manufacturer's instructions. Real-time quantitative RT-PCR was performed using 
custom-made RT-PCR enzymes and reagents kit (Invitrogen Life Technology Inc, 
Carlsbad, CA) and ASl Prism 7700 Sequence Detector (FE Applied Biosciences, 
Foster City, CA). Primers and probes for analysis of the expression of different genes 
were designed using Primer Express Software (PE Applied Biosciences, Foster City, 
CAl· 
For the analysis, 100 ng aftatal RNA was used. Each RNA sample was run in 
duplicate and the mean value was used to calculate the gene expression level. 
Fat Absorption 
For the following experiments, the rats were treated and stool collected by Ameya 
Kulkarni. Stool was then sent to Ron landacek for fat absorption analysis. 
13 
To measure intestinal fat absorption in ASO treated rats, three groups of rats were 
treated with either Saline (n~5), negative control ASO (n~5) or DGAT2 (n~5) under 
high fat feeding conditions as described above. During the third week of the 
treatment period, fat absorption was measured by placing a sucrose polybehenate 
marker in a safflower oil diet and measuring the percent discarded in collected stool 
samples29. 
Histologic Analysis. 
Liver and epididymal fat were fixed in 10% buffered fonnalin and embedded in 
paraffin wax, Multiple adjacent 4-um sections were cut and amounted on glass slides. 
After dehydration, the sections were stained with hematoxylin and eosin. Images of 
the histological sections were analyzed by Isis Phannaceuticals. 
Statistical Analysis 
Data are expressed as means ± S,E.M. The significance of the differences in mean 
values among different treabnent groups were evaluated using the one way-ANOV A, 
14 




Consistency of High and Low Dose Control Groups 
Weight gain and food intake were similar in all groups except the DGAT2 grouP. 
which showed a significantly lower weight gain over the treabnent period (Figure 3). 
As there was no significant di fference in weight gain, tissue TO content, lipid profile, 
hepatic or peripheral insulin sensitivities between the low- and high-dose negative 
control groups, the data was combined into one negative control ASO group. 
Effect of ASO on DGAT 1 and 2 Expression in Liver, White Adipose Tissue, and 
Skeletal Muscle 
Antisense Oligonucleotide therapy reduced gene expression of DGATI and 2 by 95% 
and 57% in liver when compared to scrambled ASO contro ls. Of note, there was no 
reduction in gene expression in skeletal muscle. In results consistent with previous 
data l7,1 8, DGATl and 2 expression did no t increase to compensate for deficiency of 
the other enzyme (Figure 2), There was no evidence of hepatotoxicity, as assessed by 
serum-transaminase concentrations and no variations in food intake between the 
groups. 
Effect of Reduced DGAT 1 and 2 Expression on Food Consumption and Weight 
Gain 
Although food consumption was consistent across a11 treatment groups (Figure 3), 
final weights were significantly lower in the DGAT 2 treated animals (374±7.6 vs. 
415±9.4, 412 ±6.0, 404±7.6 and 418±9.1 g for DGA T2 vs Saline/RC, SalineIHFD, 
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ScrambledIHFD and DGATl; p<O.05) (Figure 3) Weight gain efficiency, the ratio of 
weight gain to food consumption, was significantly lower in DGA T2 
group(0.26±0.02 vs. 0.3I±O.02, 0.30 ±O.OI and 0.33±0.OI for DGAT2 vs 
Saline/HFD, ControllHFD and DGATI, p<0.05) strongly suggesting that the reduced 
weight gain in the DGA T2 ASO group was metabolic and not secondary to reduced 
appetite. 
Further evidence for a metabolic cause of reduced weight gain in the DGAT 2 
treabnent group was provided by specific study of intestinal fat absorption by SBp29, 
This ex.periment revealed no difference in fat absorption between rats treated with the 
DGA T2 ASO and controls. 
Reduction 0/ DGAT2 Gene Expression Reduced Hepatic Triglyceride Content and 
Improved Plasma Lipid Levels. 
Histologic examination (Figure 4) and analysis of liver triglyceride content (9.2±1.1 
vs. 20.1±1.5, 15.9 ±1.4 and 17.0±2.4 mglg wet liver for DGAT2 vs Saline/HFD, 
ControllHFD and DGATI; p<O.OS) demonstrated significant improvement in hepatic 
steatosis in DGA T2 ASO treated rats when compared to controls (Figure 5): There 
was, however, no significant change in muscle triglyceride content. DGAT2 
treatment also improved blood lipid levels, with plasma triglyceride levels 25% lower 
than scrambled ASO controls (26.2 ± 1.1 vs 35.2±2.4 mgldl in scrambled; p<O.OI). 
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Reduction of DGAT2 Gene Expression Improved Hepatic and Peripheral Insulin 
Sensitivities. 
The impact of treatment with the DGAT ASO on peripheral and hepatic insulin action 
was examined with 135 min hyperinsulinemic euglycemic clamps in male SD rats 
following 4 weeks of treatment with antisense oligonucleotides. Overnight fasted 
plasma glucose concentrations did not differ among the groups. During the clamp, 
the plasma insulin concentration was elevated to approximately 600pM, while the 
plasma glucose concentration was clamped at approximately 5.6 roM in all groups. 
The glucose infusion rate (GINF) required to maintain eugJycemia achieved steady 
state within 90 min and as a result, all insulin sensitivity indices were calculated after 
this point. DGAT2 treatment increased whole body insulin response, as reflected by a 
significantly higher GINF (24.0±0.9 vs. 16.7±1.2, 11.7 ±1.0, 14.0±0.9 and !3. 1±1.7 
mglkg'min far DGA T2 vs SalineIRC, SalineIHFD, CantrollHFD and DGA T1; 
p<0.05) (Figure 6A). 
To discern the individual contributions of liver and peripheral tissue to increased 
insulin response, insulin action on liver and peripheral tissue were measured 
separately using radioisotope labeled glucose infused during the clamp. While basal 
hepatic glucose production was similar in all groups, insulin stimulated suppression 
of hepatic glucose production, a marker of hepatic insulin sensitivity. was 
significantly increased in the DGAT2 treatment group when compared to controls 
(82.1± 5.5 vs. 48.5± 1.5, 50.4 ±9.5 and 47.5±9.2 % for DGAT2 vs SalinelHFD, 
CantrollHFD and DGA T1; p<0.05) (Figure 6B). 
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Moreover, DGA T2 ASO treatment increased insulin stimulated whole body glucose 
uptake and glycogen synthesis rates by47% and 71 % when compared to controls 
(Figure 6C). This increase in insulin stimulated glucose uptake was predominantly 
accounted for by a 35% and 230% increase in insulin stimulated glucose uptake in 
skeletal muscle (Figure 6D) and white adipose tissue (Figure 6E), suggesting a 
significant improvement in peripheral insulin sensitivity. 
The DGAT2 ASO treatment group also demonstrated significantly lower free fatty 
acid (FFA) levels during the clamp period as well as a 64% reduction ofFFA under 
insulin stimulation (Figure 7), implying an improvement in insulin sensitivity towards 
suppression oflipolysis from adipose tissue as well. 
Of note, DGATI suppression did not result in any improvement in hepatic or 
peripheral insulin sensitivity. 
Reduction of DGAT2 Reduced Intracellular Levels of Diacylglycerol 
Levels of diacylglycerol and long chain acyl CoA were examined in the hepatocytes 
of rats treated with either scrambled or DGA T2 ASOs for four weeks under high fat 
feeding conditions. Although there was no significant difference in long chain acyl 
eoAs between the two groups(80.2+8.6 vs 82.8+13.3), diacylglycerol levels were 




This study demonstrated that liver and adipose tissue specific inhibition of DGA T2 
via ASO results in reduced weight gain, less hepatic steatosis and improved hepatic 
and peripheral insulin sensitivity in rats fed a high fat diet. Previous studies 
examining the effects of DGA T2 deficiency used a whole body knockout model, 
which resulted in severe lipopenia, excessively thin skin and early neonatal death 
secondary to dehydration IS • Because the ASO in this study specifically targeted liver 
and adipose tissue l9, there was no lipopenia in the peripheral tissue or epidermis and 
thus no peripheral toxicity occurred from DGA T2 deficiency. In addition, the results 
of this study showed no differences in intestinal fat absorption or food consumption 
in DGATI deficient animals versus controls, and no hepatotoxicity secondary to 
treatment. This strongly supports the idea that the mechanisms behind the 
improvements in weight, hepatic fat, and insulin sensitivity are metabolic. 
Interestingly, despite the liver and adipose specific effect of the ASO, this study did 
demonstrate some improvement in peripheral insulin resistance, specifically in 
skeletal muscle. There are several potential explanations for this phenomenon, 
including an improvement in the general metabolic state of treated animals or a 
previously unknown muscle specific effect of the ASO. Specific examination of the 
fatty acid metabolites in muscle is currently being done to determine the causes of 
this interesting occurrence. 
In another important finding in the current study, liver and adipose specific deficiency 
ofDGATl did not result in any improvement in insulin sensitivity or hepatic steatosis. 
This is in stark contrast to previous studies involving whole body deficiency of 
DGATl , which resulted in a significantly improved insulin sensitivity profile I6.17. 
Other studies have demonstrated increased activity in mice deficient in DGA Tl 30, 
likely due to an effect ofDGATI deficiency in the central nervous system. As this 
study has shown no protection from insulin resistance in rats with a liver specific 
deficiency in DGATl, the improvement in insulin sensitivity demonstrated in 
previous studies is probably due to weight loss secondary to increased activity. 
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The important role ofDGAT2 in hepatic triglyceride synthesis and the pathogenesis 
of insulin resistance has been explored in this study. It is well known that under high 
fat feeding conditions, the triglyceride synthesis pathway is activated, and the enzyme 
activities of the metabolic intermediates, including DGAT, are increased. In rats 
treated with the DGA T2 ASO, the final step--acylatlon of diacylglycerol to fonn 
triacylglycerol-cannot be completed, and thus triglyceride accumulation is 
prevented, As several studies have linked the accumulation oftriglycerides in liver 
with the pathogenesis of insulin resistance20•31 , it can be suggested that the 
improvement in insulin sensitivity demonstrated in this study is likely linked to the 
reduction in hepatic triglyceride content also observed. 
Complicating this hypothesis, however, is the assumed byproduct of reduced DGAT2 
activity-the accumulation of diacylgycerol or another intermediate product of 
triglyceride synthesis (Figure 1). Previous studies have linked the accumulation of 
these metabolities, especially diacylglycerol, to insulin resistance32, It has been 
shown that diacylglycerol activates several PKC isomers, which in tum induces 
serine/threonine phosporylation of the insulin receptor. This blocks tyrosi ne kinase 
activity on the insulin rec~tor, which induces insulin resistance!o.2o. 
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Interestingly, analysis ofhepatocytes in the rats in the current study revealed no 
increased accumulation of diacylglycerol or Acyl eoA species (Figure 8). This data, 
while resolving the conflict with previous data, suggests that an alternate metabolic 
pathway is activated in these rats to reduce fatty metabolite accumulation. In-vitro 
data in Tat hepatocytes treated with the DGA 1'2 ASO suggests a shift in the primary 
function of the cell from lipid synthesis to fatty acid oxidation33 (Figure 9). In other 
models involving specific deficiency of the mediators of lipid synthesis, similar data 
has been found. Knockout of Stearoyl-CoA desaturase, the rate limiting step in 
monosaturated fatty acid synthesis, increases fatty acid oxidation, likely through a 
pathway involving AMPK inactivation of Acetyl eoA carboxylase and downstream 
effects on Malonyl eoA 34. Other models with increased fatty acid oxidation use 
different intennediates, including peroxisome proliferators-activated receptor 
(PPARa.) and SREBPlc. The specific mediators involved in the DGAT2 deficient 
model are as yet undetennined. However, the use of the antisense o ligonucleotide 
may provide the tools necessary to identify the key pathways utilized in this process. 
In summary, rats with phannacologicaUy induced deficiency in DGAT2 have less 
hepatic steatosis and are protected from insulin resistance under high fat feeding 
condi tions. In addition, our results suggest that the deficiency in DGA T2 shifts the 
primary pathway oflipid in the liver from synthesis to oxidation. Use of the antisense 
oligonucleotide in this study has provided the unique opportunity to study the 
metabolic role ofDGAT2 in the liver and adipose tissue separate from developmental 
effects associated with the whole-body knockout model. Equally important) however, 
is the potential for DGA T2 as a potential therapeutic target for reduction of hepatic 
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F igure t . TrigyJceride Synthesis Pathway 
The two isoforms of DiacyJglycerol Acyltransferase (DGATI and DGAT2) catalyze 
the final step in both the de-novo and fe-esterification pathways leading (0 
triglyceride synthesis. Prior to addition of an acyl-CoA group to diacylglyerol to 
form triacylglycerol, several other enzymes, including Acyl-CoA:gJycerol-sn-3-
phosphate acyl transferase (GPAT), acyl-CoA: l-acylglycerol-sn-3-phosphate 
acyltransferase (AGPAT) and phosphatidic acid phosphatase (PAP) sequentially add 
acyl-CoA groups to several intermediates, beginning with Glycerol-3-phosphate. 
Glycerol 3 phosphate is generated de-novo or via fe-esterificalion of the products of 
fatty acid oxidation. 
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DGAT 1 & 2 Gene Expression in Liver 
DGAT1 Gene Bcpressiorl OGAT2 gme Exp e:ssior. 
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Figure 2. DGATI and DGAT2 Gene expression after ASO treatment 
WT animals were treated with a nonsense (scrambled). DGATl, or DGAT2 ASO for 
four weeks while on a high-fat die. (SCR",scrambJed ASO, DGATI =DGA TI ASO 
Treatment, DGAT2=DGAT2 ASO Treatment). Baseline values of gene expression 
were measured in a separate group prior to treatment. Gene expression was measured 
in rats receiving four weeks of treatment. Livers were collected under fasti ng 
conditions using an in-situ freeze-clamp technique. Values expressed as percent 
suppression from baseline + SEM. 
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Figu re 3. Body Weight Gain and Food Consumption during treatment period. 
Body weight and food consumption was measured biweekly immediately prior to 
treatment in all treatment groups-Saline treatment on regu lar chow (SIRe), Saline 
treatment on high fat diet (SIHFD), Scrambled ASO treatment on high fat diet (SeR), 
DGATI ASO treatment on high fat diet (DGATl), and DGA 1'2 ASO treatment on 
high fat diet (DGA T2)-over the four week treatment period. Results are expressed 
III grams. 
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Figure 4. Histologic Analysis of Hepatocytes 
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Representative histology of rat hepatocytes after four weeks of either Saline treatment 
on regular chow, Saline treatment on a high fat diet, Scrambled ASO treatment on a 










Triglyceride content in liver 
P<O.05 
Scrambled OGAT1 DGAT2 
H;gh Fat 0 ;011- ----'1 
Figure 5. Triglyceride Content in Liver 
3 1 
Liver triglyceride content was measured in all five groups at the end of the four week 
treatment period. Rats were given regular chow or a high fat diet and treated with 
saline, nonsense (scrambled) ASO, DGATI ASO, or DGAT2 ASO. Livers were 
obtained via in-situ freeze clamping after overnight fast. Results are expressed as 
mean triglyceride content (in milligrams per gram of liver) + SEM. 
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Figure 5. Triglyceride Content in Liver 
Liver triglyceride content was measured in all five groups at the end of the four week 
treatment period. Rats were given regu lar chow or a high fat diet and treated with 
saline, nonsense (scrambled) ASO, DGATI ASO, or DGATI ASO. Livers were 
obtained via in-situ freeze clamping after overnight fast. Results are expressed as 
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Figure 6. Hyperinsulinemic-Euglycemic Clamp Experiments 
Wild-type rats were separated in into five treatment groups: Saline treatment in rats 
receiving regular chow (SIRe; 0""7), saline treatment in rats receiving a high fat diet 
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(S/HF; n= 7), and high fat fed rats receiving treatment with either a nonsense ASO 
(SCR; n=14), DGATl ASO (DGATl; 0=11), or DGATl ASO (DGAT2; n=9). After 
a 14 hour fast. all treatment groups underwent hyperinsulinemic-euglycemic (4 
mU/kg/rnin ) clamp experiments. Plasma glucose was maintained by variable 
intravenous infusion of 20% gl ucose, as recorded (A). Once steady stale conditions 
were achieved, insulin-mediated suppression of hepatic glucose production was 
determined (B). to addition, steady state whole body glucose uptake, glycolys is, and 
glycogen synthesis were measured(C). [ndividual tissue uptake of glucose in skeletaJ 
muscle CD) and adipose tissue eE) was determined using the 3H radioactive marker. 
All values are expressed as means ± SEM. 
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Figure 7. Insulin effect on plasma free fatty acid concentration. 
In all fi ve experimental groups, after the treatment period and an overnight fast , 
plasma was drawn at baseline (time = 0) and again at 185 minutes after insulin 
stimulation (during the hyperinsulinemic-euglycemic clamp) to measure insulin 
stimulated suppression of plasma free fatty ac id concentration. Results are expressed 
as mean percentage suppression + SEM. 
• 
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lipid Metabolities in liver 
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Figure 8. Meas urement of lipid metaboli tes 
After a 14 hour fast, Long chain acyl-CoA (A) and diacylglycerol (B) species were 
extracted from the livers of rats from the nonsense and DGA T2 ASO treatment 
groups. An API 3000 tandem mass spectrometer interfaced with a turbo ions pray 
source in negative electrospray mode measured individual species. Values shown are 
means+ SEM. 
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Figure 9. Effect of DGATI ASO on triglyceride synthesis and fat oxidation in 
cultured rat hepatocytes. 
Rat hepatocytes were transfected with either a nonsense or DGA 1'2 ASO. Once it 
was determined that gene expression was suppressed (A), trigy1ceride synthesis in 
transfected rat bepatocytes was determined by measuring the incorporation of 
radiolabeled glycerol in to triglycerides with and without oleate (B). a cmcial 
compound for de novo synthesis. Fat oxidation was then measured (C). All values in 
mean + SEM. 
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Figure 7. lnsulin effect on plasma free fatty acid concentration. 
In all five experimental groups, after the treatment period and an overnight fast, 
plasma was drawn at baseline (time = 0) and again at 185 minutes after insulin 
stimulation (during the hyperinsulinemic-euglycemic clamp) to measure insulin 
stimulated suppression of plasma free fatty acid concentration. Results are expressed 
as mean percentage suppression + SEM. 
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Figure 7. lnsulin effect on plasma free fatty acid concenLration. 
In all five experimental groups, after the treatment period and an overnight fast, 
plasma was drawn at baseline (time = 0) and again at 185 minutes after insulin 
stim ulation (during the hyperinsulinemic-euglycemic clamp) to measure insulin 
stimulated suppression of plasma free fatty acid concentration. Results are expressed 
as mean percentage suppression + SEM. 
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After a 14 hour fast, Long chain acyl-eoA (A) and diacylglycerol (B) species were 
extracted from the livers of rats from the nonsense and DGA 1'2 ASO treatment 
groups. An API 3000 tandem mass spectrometer interfaced with a turbo ionspray 
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source in negative electrospray mode measured individual species. Values shown are 
means + SEM. 
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Figure 9. Effect of DGA 1'2 ASO on triglyceride synthesis and fat oxidation in 
cultured rat hepatocytes. 
Rat hepatocytes were transfected with either a nonsense or DGATI ASO. Once it 
was determined that gene expression was suppressed (A). trigylceride synthesis in 
transfected rat hepatocytes was determined by measuring the incorporation of 
radiolabeled glycerol into triglycerides with and without oleate (B). a crucial 
compound for de novo synthesis. Fat oxidation was then measured (C). All values in 
mean + SEM. 
HARVEY CUSHING/JOHN HAY WHITNEY 
MEDICAL LIBRARY 
MANUSCRIPT THESES 
Unpublished theses submitted for the Master's and Doctor's 
degrees and deposited in the Medical Library are to be used only with 
due regard to the rights of the authors. Bibliographical references 
may be noted, but passages must not be copied without permission of 
the authors, and without proper credit being given in subsequent 
written or published work. 
This thesis by 
has been used by the following person, whose signatures attest their 
acceptance of the above restrictions. 
NAME AND ADDRESS DATE 
